ASP 7398Alternative Names: ASP7398
Latest Information Update: 26 Feb 2016
At a glance
- Originator Astellas Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Nocturia
Most Recent Events
- 26 Feb 2016 Phase-I clinical trials in Nocturia in Japan (unspecified route) prior to January 2016 (Astellas' pipeline, January 2016)